Arterial and venous thrombosis: shared risk factors and pathophysiology
Keywords:
-Abstract
-
Downloads
Download data is not yet available.
References
1. ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost. 2014;12:1580-90.
2. Sørensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet. 2007;370:1773-9.
3. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a metaanalysis. Circulation. 2008;117:93-102.
4. Cavallari I, Morrow DA, Creager MA, Olin J, Bhatt DL, Steg PG, et al. Frequency, predictors, and impact of combined antiplatelet therapy on venous thromboembolism in patients with symptomatic
atherosclerosis. Circulation. 2018;137:684-92.
5. Savchenko AS, Martinod K, Seidman MA, Wong SL, Borissoff JI, Piazza G, et al. Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism
development. J Thromb.Haemost. 2014;12:860-70.
6. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr, Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360:1851-61.
7. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ. 1994;308:235-46.
8. Pulmonary Embolism Prevention (PEP) trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355:1295-302
9. Simes J, Becattini C, Agnelli G, Eikelboom JW, Kirby AC, Mister R, et al. INSPIRE Study Investigators (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism). Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation. 2014;130:1062-71.
10. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, et al. WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366:1959-67.
11. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367:1979-87.
12. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319-30.
13. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353:1167-73.
14. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. On behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study. Lancet. 2004;364:937-52.
15. Croce K, Libby P. Interwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol. 2007;14:55-61.
16. Rumley A, Emberson JR, Wannamethee SG, Lennon L, Whincup PH, Lowe GD. Effects of older age on fibrin D-dimer, C-reactive protein and other hemostatic and inflammatory variables in men aged 60-79 years. J Thromb Haemost. 2006;4:982-7.
17. Wannamethee SG, Lowe GD, Whincup PH, Rumley A, Walker M, Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation. 2002;105:1785-90.
18. Prandoni P, Villalta S, Tormene D, Spiezia L, Pesavento R. Immobilization resulting from chronic medical diseases: a new risk factor for recurrent venous thromboembolism in anticoagulated patients. J Thromb Haemost. 2007;5:1786-7.
19. Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol. 2008;83:97-102.
20. Ray JG. Dyslipidemia, statins and venous thromboembolism: a potential risk factor and a potential treatment. Curr Opin Pulmo Med. 2003;9:378-84.
21. Squizzato A, Romualdi E, Ageno W. Why should statins prevent venous thromboembolism? A systematic literature search and a call for action. J Thromb Haemost. 2006;4:1925-7.
22. Levine MN, Lee AY, Kakkar AK. From Trousseau to targeted therapy; new insights and innovations in thrombosis and cancer. J Thromb Haemost. 2003;1:1456-63.
23. Grilz E, Marosi C, Königsbrügge O, Riedl J, Posch F, Lamm W, et al. Association of complete blood count parameters, d-dimer, and soluble P-selectin with risk of arterial thromboembolism in patients with cancer. J Thromb Haemost. 2019;17:1335-44.
24. Lowe GDO. Update on the cardiovascular risks of hormone replacement therapy. Women’s Health 2007;3:87-97.
25. Wu O, Robertson L, Twaddle S, Lowe G, Clark P, Walker I, et al. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol. 2005;131:80-90.
26. Bloemenkamp KMM, Helmerhorst FM. The oral contraceptive pill, mechanisms of vascular risk, and practical prescribing strategies for women with thrombotic problems. In: Greer IA, Ginsberg J, Forbes CD, editors. Women’s Vascular Health. London: Hodder Arnold;2007; p. 423-35.
27. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611-8.
28. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006;367:1075-9.
29. Lijfering WM, Ten Kate MK, Sprenger HG, van der Meer J. Absolute risk of venous and arterial thrombosis in HIV infected patients and effects of combination antiretroviral therapy. J Thromb Haemost. 2006;4:1928-30.
30. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J. 2003;146:948-57.
31. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, et al. Seven haemostatic polymorphisms and coronary disease: a meta analysis comprising 66155 cases and 91307 controls. Lancet. 2006;367:651-8.
32. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe GDO. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic
stroke? The Caerphilly Study. Circulation. 2005;112:3080-7.
33. Lowe GDO. Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture. Br J Haematol. 2006;133:232-50.
2. Sørensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet. 2007;370:1773-9.
3. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a metaanalysis. Circulation. 2008;117:93-102.
4. Cavallari I, Morrow DA, Creager MA, Olin J, Bhatt DL, Steg PG, et al. Frequency, predictors, and impact of combined antiplatelet therapy on venous thromboembolism in patients with symptomatic
atherosclerosis. Circulation. 2018;137:684-92.
5. Savchenko AS, Martinod K, Seidman MA, Wong SL, Borissoff JI, Piazza G, et al. Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism
development. J Thromb.Haemost. 2014;12:860-70.
6. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr, Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360:1851-61.
7. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ. 1994;308:235-46.
8. Pulmonary Embolism Prevention (PEP) trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355:1295-302
9. Simes J, Becattini C, Agnelli G, Eikelboom JW, Kirby AC, Mister R, et al. INSPIRE Study Investigators (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism). Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation. 2014;130:1062-71.
10. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, et al. WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366:1959-67.
11. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367:1979-87.
12. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319-30.
13. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353:1167-73.
14. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. On behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study. Lancet. 2004;364:937-52.
15. Croce K, Libby P. Interwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol. 2007;14:55-61.
16. Rumley A, Emberson JR, Wannamethee SG, Lennon L, Whincup PH, Lowe GD. Effects of older age on fibrin D-dimer, C-reactive protein and other hemostatic and inflammatory variables in men aged 60-79 years. J Thromb Haemost. 2006;4:982-7.
17. Wannamethee SG, Lowe GD, Whincup PH, Rumley A, Walker M, Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation. 2002;105:1785-90.
18. Prandoni P, Villalta S, Tormene D, Spiezia L, Pesavento R. Immobilization resulting from chronic medical diseases: a new risk factor for recurrent venous thromboembolism in anticoagulated patients. J Thromb Haemost. 2007;5:1786-7.
19. Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol. 2008;83:97-102.
20. Ray JG. Dyslipidemia, statins and venous thromboembolism: a potential risk factor and a potential treatment. Curr Opin Pulmo Med. 2003;9:378-84.
21. Squizzato A, Romualdi E, Ageno W. Why should statins prevent venous thromboembolism? A systematic literature search and a call for action. J Thromb Haemost. 2006;4:1925-7.
22. Levine MN, Lee AY, Kakkar AK. From Trousseau to targeted therapy; new insights and innovations in thrombosis and cancer. J Thromb Haemost. 2003;1:1456-63.
23. Grilz E, Marosi C, Königsbrügge O, Riedl J, Posch F, Lamm W, et al. Association of complete blood count parameters, d-dimer, and soluble P-selectin with risk of arterial thromboembolism in patients with cancer. J Thromb Haemost. 2019;17:1335-44.
24. Lowe GDO. Update on the cardiovascular risks of hormone replacement therapy. Women’s Health 2007;3:87-97.
25. Wu O, Robertson L, Twaddle S, Lowe G, Clark P, Walker I, et al. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol. 2005;131:80-90.
26. Bloemenkamp KMM, Helmerhorst FM. The oral contraceptive pill, mechanisms of vascular risk, and practical prescribing strategies for women with thrombotic problems. In: Greer IA, Ginsberg J, Forbes CD, editors. Women’s Vascular Health. London: Hodder Arnold;2007; p. 423-35.
27. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611-8.
28. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006;367:1075-9.
29. Lijfering WM, Ten Kate MK, Sprenger HG, van der Meer J. Absolute risk of venous and arterial thrombosis in HIV infected patients and effects of combination antiretroviral therapy. J Thromb Haemost. 2006;4:1928-30.
30. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J. 2003;146:948-57.
31. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, et al. Seven haemostatic polymorphisms and coronary disease: a meta analysis comprising 66155 cases and 91307 controls. Lancet. 2006;367:651-8.
32. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe GDO. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic
stroke? The Caerphilly Study. Circulation. 2005;112:3080-7.
33. Lowe GDO. Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture. Br J Haematol. 2006;133:232-50.
Downloads
Published
2019-12-23
Issue
Section
บทความฟื้นวิชา (Literature review)
